相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥60 years old with relapsed or refractory B-cell lymphoma
Ajay K. Gopal et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma
D. S. Ritchie et al.
ANNALS OF HEMATOLOGY (2007)
A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150
A. Belch et al.
ANNALS OF ONCOLOGY (2007)
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Peter Dreger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
Marco Ladetto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
B. S. Kahl et al.
ANNALS OF ONCOLOGY (2006)
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
C Pott et al.
BLOOD (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Cyclin D1-negative mantle cell lymphoma:: a clinicopathologic study based on gene expression profiling
K Fu et al.
BLOOD (2005)
Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma
D Bauwens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
C Thieblemont et al.
CANCER (2005)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations
H Luo et al.
BLOOD (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP
DW Thomas et al.
LEUKEMIA & LYMPHOMA (2005)
Hematopoietic stem cell transplantation in mantle cell lymphoma
AK Ganti et al.
ANNALS OF ONCOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
YL Kasamon et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
J Mangel et al.
ANNALS OF ONCOLOGY (2004)
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
MB Maris et al.
BLOOD (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
H Kaufmann et al.
BLOOD (2004)
Transplantation in patients with diffuse mantle cell lymphoma in first disease remission the prognostic value of β2-microglobulin and the tumor score
IF Khouri et al.
CANCER (2003)
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma:: outcome related to remission pretransplant
NS Andersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni et al.
BLOOD (2003)
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
J Orchard et al.
BLOOD (2003)
Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada clinical trials group
CT Kouroukis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Outcome of autologous transplantation for mantle cell lymphoma:: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant registries
E Vandenberghe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
JE Romaguera et al.
CANCER (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy
G Freyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
IF Khouri et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
SP Robinson et al.
BLOOD (2002)
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
AK Gopal et al.
BLOOD (2002)
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma:: a prospective study
F Lefrère et al.
LEUKEMIA (2002)
A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors
NS Andersen et al.
EUROPEAN JOURNAL OF CANCER (2002)
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
OM Howard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
JW Sweetenham
BONE MARROW TRANSPLANTATION (2001)
Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
BJ Cohen et al.
LEUKEMIA & LYMPHOMA (2001)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Untreated aggressive mantle cell lymphoma: Results with intensive chemotherapy without stem cell transplant in elderly patients
JE Romaguera et al.
LEUKEMIA & LYMPHOMA (2000)
分享论文
